The growing interest in and prevalence of the use of psychedelics, as well as the potential benefits and negative consequences associated with psychedelic experiences, create a need for mental health specialists to be able to provide adequate and effective intervention regarding the content and consequences of these experiences, that is, psychedelic integration. At the same time, current graduate training in psychiatry, psychology, psychotherapy, counseling, etc., fails to adequately prepare professionals for such interventions. In order to fill this gap, an international, bottom-up project was established to attempt developing guidelines. This project was conducted by means of literature reviews as well as roundtable discussions among project participants, leading to a consensus on the guidelines' final scope and content. Drawing from the outcomes of this project, this article presents proposed comprehensive guidelines covering both theoretical and practical aspects of psychedelic integration, that are intended to serve as a resource for various mental health specialists who may encounter individuals in need of support considering their psychedelic experiences. These guidelines encompass clinician-friendly information on the effects of psychedelics, a definition of psychedelic integration, the general theoretical considerations linked to utilization of psychedelic experiences in clinical practice, a simple model organizing the course of psychedelic integration practice, as well as an overview of the current models of psychedelic integration, along with a selective presentation of basic and specific interventions derived from various psychotherapeutic approaches that can be employed in the practice of psychedelic integration.

3rd Medical Faculty Charles University Prague Prague Czechia

Czech Psychedelic Society Prague Czechia

Multidiszciplináris Társaság a Pszichedelikumok Kutatásáért Budapest Hungary

National Institute of Mental Health Klecany Czechia

Polish Psychedelic Society Warsaw Poland

Polish Society of Process Psychology Warsaw Poland

Psyon Psychedelic Clinic Prague Czechia

Public Health Department Institute of Psychiatry and Neurology Warsaw Poland

Zobrazit více v PubMed

Aday J. S., Mitzkovitz C. M., Bloesch E. K., Davoli C. C., Davis A. K. (2020). Long-term effects of psychedelic drugs: a systematic review. Neurosci. Biobehav. Rev. 113, 179–189. doi: 10.1016/j.neubiorev.2020.03.017, PMID: PubMed DOI

Aixalà B. M. (2022). Psychedelic integration: Psychotherapy for non-ordinary states of consciousness. United States: Synergetic Press

Allen J. G., Romate J., Rajkumar E. (2021). Mindfulness-based positive psychology interventions: a systematic review. BMC Psychol. 9, 1–18. doi: 10.1186/s40359-021-00618-2, PMID: PubMed DOI PMC

Andersen K. A., Carhart-Harris R., Nutt D. J., Erritzoe D. (2021). Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies. Acta Psychiatr. Scand. 143, 101–118. doi: 10.1111/acps.13249, PMID: PubMed DOI

Badour C. L., Feldner M. T. (2013). Trauma-related reactivity and regulation of emotion: associations with posttraumatic stress symptoms. J. Behav. Ther. Exp. Psychiatry 44, 69–76. doi: 10.1016/j.jbtep.2012.07.007, PMID: PubMed DOI PMC

Baer R. A. (2015). Mindfulness-based treatment approaches: clinician's guide to evidence base and applications. Amsterdam, Netherlands: Elsevier.

Barrett F. S., Johnson M. W., Griffiths R. R. (2017). Neuroticism is associated with challenging experiences with psilocybin mushrooms. Personal. Individ. Differ. 117, 155–160. doi: 10.1016/j.paid.2017.06.004, PMID: PubMed DOI PMC

Bathje G. J., Majeski E., Kudowor M. (2022). Psychedelic integration: an analysis of the concept and its practice. Front. Psychol. 13:824077. doi: 10.3389/fpsyg.2022.824077, PMID: PubMed DOI PMC

Bourzat F., Hunter K. (2019). Consciousness medicine: indigenous wisdom, entheogens, and expanded. States of consciousness for healing healing and growth. Berkeley, CA: North Atlantic Books.

Bouso J. C., Palhano-Fontes F., Rodríguez-Fornells A., Ribeiro S., Sanches R., Crippa J. A. S., et al. . (2015). Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. Eur. Neuropsychopharmacol. 25, 483–492. doi: 10.1016/j.euroneuro.2015.01.008, PMID: PubMed DOI

Brennan W., Belser A. B. (2022). Models of psychedelic-assisted psychotherapy: a contemporary assessment and an introduction to EMBARK, a Transdiagnostic, trans-drug model. Front. Psychol. 13:866018. doi: 10.3389/fpsyg.2022.866018, PMID: PubMed DOI PMC

Brown K. W., Ryan R. M. (2003). The benefits of being present: mindfulness and its role in psychological well-being. J. Pers. Soc. Psychol. 84, 822–848. doi: 10.1037/0022-3514.84.4.822 PubMed DOI

Bryant R. A. (2017). Acute stress disorder. Curr. Opin. Psychol. 14, 127–131. doi: 10.1016/j.copsyc.2017.01.005, PMID: PubMed DOI

Buller K., Moore J. (2019). Integration workbook: Planting seeds for growth and change. Scotts Valley, CA: CreateSpace Independent Publishing Platform.

Carbonaro T. M., Bradstreet M. P., Barrett F. S., MacLean K. A., Jesse R., Johnson M. W., et al. . (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J. Psychopharmacol. 30, 1268–1278. doi: 10.1177/0269881116662634, PMID: PubMed DOI PMC

Carhart-Harris R. L., Friston K. (2019). REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacol. Rev. 71, 316–344. doi: 10.1124/pr.118.017160, PMID: PubMed DOI PMC

Carhart-Harris R. L., Leech R., Erritzoe D., Williams T. M., Stone J. M., Evans J., et al. . (2013). Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. Schizophr. Bull. 39, 1343–1351. doi: 10.1093/schbul/sbs117, PMID: PubMed DOI PMC

Carhart-Harris R. L., Leech R., Hellyer P. J., Shanahan M., Feilding A., Tagliazucchi E., et al. . (2014). The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front. Hum. Neurosci. 8:20. doi: 10.3389/fnhum.2014.00020, PMID: PubMed DOI PMC

Carhart-Harris R. L., Roseman L., Haijen E., Erritzoe D., Watts R., Branchi I., et al. . (2018). Psychedelics and the essential importance of context. J. Psychopharmacol. 32, 725–731. doi: 10.1177/0269881118754710, PMID: PubMed DOI

Carmo Carvalho M., Pinto de Sousa M., Frango P., Dias P., Carvalho J., Rodrigues M., et al. . (2014). Crisis intervention related to the use of psychoactive substances in recreational settings-evaluating the Kosmicare project at boom festival. Curr. Drug Abuse Rev. 7, 81–100. doi: 10.2174/1874473708666150107115515, PMID: PubMed DOI

Coden K. E. (2017). After the ceremony ends: A companion guide to help you integrate visionary plant medicine experiences. Baltimore, Maryland: Shine Mojo, LLC.

Cohen I. (2017). Re-turning to wholeness: The psycho-spiritual integration process of Ayahuasca ceremonies in Western participants from a Jungian Perspctive. San Francisco, CA: California Institute of Integral Studies.

Cox P. D., Vinogradov S., Yalom I. D. (2008). “Group therapy” in The American Psychiatric Publishing textbook of psychiatry. eds. Hales R. E., Yudofsky S. C., Gabbard G. O. (United States: American Psychiatric Publishing, Inc.), 1329–1373.

Dakic V., Minardi Nascimento J., Costa Sartore R., Maciel R. D. M., de Araujo D. B., Ribeiro S., et al. . (2017). Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT. Sci. Rep. 7, 1–13. doi: 10.1038/s41598-017-12779-5 PubMed DOI PMC

Davis A. K., Barrett F. S., Griffiths R. R. (2020). Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. J. Contextual Behav. Sci. 15, 39–45. doi: 10.1016/j.jcbs.2019.11.004, PMID: PubMed DOI PMC

Earleywine M., Low F., Lau C., De Leo J. (2022). Integration in psychedelic-assisted treatments: recurring themes in current providers’ definitions, challenges, and concerns. J. Humanist. Psychol. 2022:858. doi: 10.1177/00221678221085800 DOI

Fadiman J. (2011). The psychedelic explorer's guide: Safe, therapeutic, and sacred journeys. Noida: Simon and Schuster. PubMed

Gandy S., Forstmann M., Carhart-Harris R. L., Timmermann C., Luke D., Watts R. (2020). The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health. Health Psychol. Open 7:978123. doi: 10.1177/2055102920978123, PMID: PubMed DOI PMC

Garcia-Romeu A., Richards W. A. (2018). Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. Int. Rev. Psychiatry 30, 291–316. doi: 10.1080/09540261.2018.1486289 PubMed DOI

Gorman I., Nielson E. M., Molinar A., Cassidy K., Sabbagh J. (2021). Psychedelic harm reduction and integration: a transtheoretical model for clinical practice. Front. Psychol. 12:645246. doi: 10.3389/fpsyg.2021.645246, PMID: PubMed DOI PMC

Griffiths R. R., Richards W. A., McCann U., Jesse R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187, 268–283. doi: 10.1007/s00213-006-0457-5, PMID: PubMed DOI

Grof S. (1976). Realms of the human unconsciousness: observations from LSD research Dutton. New York: Viking Press.

Grof S. (2014). Holotropic breathwork: a new experiential method of psychotherapy and self-exploration. J. Transpers. Res. 6, 7–24.

Grossman P., Niemann L., Schmidt S., Walach H. (2004). Mindfulness-based stress reduction and health benefits: a meta-analysis. J. Psychosom. Res. 57, 35–43. doi: 10.1016/S0022-3999(03)00573-7, PMID: PubMed DOI

Guss J., Krause R., Sloshower J. (2020). The Yale manual for psilocybin-assisted therapy of depression (using acceptance and commitment therapy as a therapeutic frame). PsyArXiv.

Halpern J. H., Lerner A. G., Passie T. (2016). A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. Behav. Neurobiol. Psychedelic Drugs 36, 333–360. doi: 10.1007/7854_2016_457, PMID: PubMed DOI

Hendricks P. S., Clark C. B., Johnson M. W., Fontaine K. R., Cropsey K. L. (2014). Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision. J. Psychopharmacol. 28, 62–66. doi: 10.1177/0269881113513851, PMID: PubMed DOI

Hendricks P. S., Thorne C. B., Clark C. B., Coombs D. W., Johnson M. W. (2015). Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J. Psychopharmacol. 29, 280–288. doi: 10.1177/0269881114565653, PMID: PubMed DOI

Hendy K. (2022). What can the chemical hold?: the politics of efficacy in the psychedelic renaissance. Cult. Med. Psychiatry 46, 322–343. doi: 10.1007/s11013-021-09708-7, PMID: PubMed DOI PMC

Holden C. (1980). Arguments heard for psychedelics probe. Science 209, 256–257. doi: 10.1126/science.7384800, PMID: PubMed DOI

Inserra A., De Gregorio D., Gobbi G. (2021). Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms. Pharmacol. Rev. 73, 202–277. doi: 10.1124/pharmrev.120.000056, PMID: PubMed DOI

Johnson M. W., Richards W. A., Griffiths R. R. (2008). Human hallucinogen research: guidelines for safety. J. Psychopharmacol. 22, 603–620. doi: 10.1177/0269881108093587, PMID: PubMed DOI PMC

Jones K. A., Srivastava D. P., Allen J. A., Strachan R. T., Roth B. L., Penzes P. (2009). Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling. Proc. Natl. Acad. Sci. 106, 19575–19580. doi: 10.1073/pnas.0905884106, PMID: PubMed DOI PMC

Killion B., Hai A. H., Alsolami A., Vaughn M. G., Oh P. S., Salas-Wright C. P. (2021). LSD use in the United States: trends, correlates, and a typology of us. Drug Alcohol Depend. 223:108715. doi: 10.1016/j.drugalcdep.2021.108715, PMID: PubMed DOI

Lutkajtis A., Evans J. (2023). Psychedelic integration challenges: participant experiences after a psilocybin truffle retreat in the Netherlands. J. Psychedelic Stud. 6, 211–221. doi: 10.1556/2054.2022.00232 DOI

Ly C., Greb A. C., Cameron L. P., Wong J. M., Barragan E. V., Wilson P. C., et al. . (2018). Psychedelics promote structural and functional neural plasticity. Cell Rep. 23, 3170–3182. doi: 10.1016/j.celrep.2018.05.022, PMID: PubMed DOI PMC

Majić T., Schmidt T. T., Gallinat J. (2015). Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences? J. Psychopharmacol. 29, 241–253. doi: 10.1177/0269881114568040, PMID: PubMed DOI

McWilliams N. (2011). The psychodynamic diagnostic manual: an effort to compensate for the limitations of descriptive psychiatric diagnosis. J. Pers. Assess. 93, 112–122. doi: 10.1080/00223891.2011.542709, PMID: PubMed DOI

Millière R. (2017). Looking for the self: phenomenology, neurophysiology and philosophical significance of drug-induced ego dissolution. Front. Hum. Neurosci. 11:245. doi: 10.3389/fnhum.2017.00245, PMID: PubMed DOI PMC

Mindell A. (1985). Working with the dreaming body. London: Routledge and Kegan Paul.

Mindell A. S. (1991). Moon in the water: The metaskills of process-oriented psychology as seen through the psychotherapeutic work of Arnold Mindell. New Delhi: The Union Institute.

Mitchell J. M., Bogenschutz M., Lilienstein A., Harrison C., Kleiman S., Parker-Guilbert K., et al. . (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat. Med. 27, 1025–1033. doi: 10.1038/s41591-021-01336-3, PMID: PubMed DOI PMC

Morgan N. L. (2020). Integrating psychedelic experiences utilizing the internal family systems therapeutic model. Int. J. Soc. Sci. Manage. Rev 3, 257–264. doi: 10.37602/IJSSMR.2020.3417 DOI

Mørkved N., Hartmann K., Aarsheim L. M., Holen D., Milde A. M., Bomyea J., et al. . (2014). A comparison of narrative exposure therapy and prolonged exposure therapy for PTSD. Clin. Psychol. Rev. 34, 453–467. doi: 10.1016/j.cpr.2014.06.005, PMID: PubMed DOI

Nichols D. E. (2016). Psychedelics. Pharmacol. Rev. 68, 264–355. doi: 10.1124/pr.115.011478, PMID: PubMed DOI PMC

Nielson E. M., Guss J. (2018). The influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training. J. Psychedelic Stud. 2, 64–73. doi: 10.1556/2054.2018.009 DOI

Noorani T., Bedi G., Muthukumaraswamy S. (2023). Dark loops: contagion effects, consistency and chemosocial matrices in psychedelic-assisted therapy trials. Psychol. Med. 2023, 1–10. doi: 10.1017/S0033291723001289 PubMed DOI PMC

Olson J. A., Suissa-Rocheleau L., Lifshitz M., Raz A., Veissière S. P. (2020). Tripping on nothing: placebo psychedelics and contextual factors. Psychopharmacology 237, 1371–1382. doi: 10.1007/s00213-020-05464-5, PMID: PubMed DOI

Ona G. (2018). Inside bad trips: exploring extra-pharmacological factors. J. Psychedelic Stud. 2, 53–60. doi: 10.1556/2054.2018.001 DOI

Ortigo K. (2021). Beyond the narrow life: a guide for psychedelic integration and existential exploration. Santa Fe, NM: Synergetic Press.

Osmond H. (1957). A review of the clinical effects of psychotomimetic agents. Ann. N. Y. Acad. Sci. 66, 418–434. doi: 10.1111/j.1749-6632.1957.tb40738.x, PMID: PubMed DOI

Passie T., Guss J., Krähenmann R. (2022). Lower-dose psycholytic therapy–a neglected approach. Front. Psych. 13. doi: 10.3389/fpsyt.2022.1020505, PMID: PubMed DOI PMC

Pavlovič I. (2020). Integration of altered states of consciousness according to the process oriented psychology. Soc Health Horiz 7:30.

Payne J. E., Chambers R., Liknaitzky P. (2021). Combining psychedelic and mindfulness interventions: synergies to inform clinical practice. ACS Pharmacol. Transl. Sci. 4, 416–423. doi: 10.1021/acsptsci.1c00034, PMID: PubMed DOI PMC

Phelps J. (2017). Developing guidelines and competencies for the training of psychedelic therapists. J. Humanist. Psychol. 57, 450–487. doi: 10.1177/0022167817711304 DOI

Pilecki B., Luoma J. B., Bathje G. J., Rhea J., Narloch V. F. (2021). Ethical and legal issues in psychedelic harm reduction and integration therapy. Harm Reduct. J. 18, 1–14. doi: 10.1186/s12954-021-00489-1 PubMed DOI PMC

Priebe S., Omer S., Giacco D., Slade M. (2014). Resource-oriented therapeutic models in psychiatry: conceptual review. Br. J. Psychiatry 204, 256–261. doi: 10.1192/bjp.bp.113.135038, PMID: PubMed DOI

Razvi S., Elfrink S. (2020). The PSIP model. An introduction to a novel method of therapy: psychedelic somatic interactional psychotherapy. J. Psychedelic Psychiatry 2, 1–24.

Resick P. A., Monson C. M., Chard K. M. (2016). Cognitive processing therapy for PTSD: A comprehensive manual. New York: Guilford Publications.

Richards W. (2015). Sacred knowledge. New York: Columbia University Press.

Roseman L., Ron Y., Saca A., Ginsberg N., Luan L., Karkabi N., et al. . (2021). Relational processes in ayahuasca groups of Palestinians and Israelis. Front. Pharmacol. 12:607529. doi: 10.3389/fphar.2021.607529, PMID: PubMed DOI PMC

Rucker J. J., Iliff J., Nutt D. J. (2018). Psychiatry and the psychedelic drugs. Past, present and future. Neuropharmacology 142, 200–218. doi: 10.1016/j.neuropharm.2017.12.040, PMID: PubMed DOI

Schlag A. K., Aday J., Salam I., Neill J. C., Nutt D. J. (2022). Adverse effects of psychedelics: from anecdotes and misinformation to systematic science. J. Psychopharmacol. 36, 258–272. doi: 10.1177/02698811211069100, PMID: PubMed DOI PMC

Sessa B. (2012). The psychedelic renaissance: Reassessing the role of psychedelic drugs in 21st century psychiatry and society. London: Muswell Hill Press.

Sexton J. D., Crawford M. S., Sweat N. W., Varley A., Green E. E., Hendricks P. S. (2019). Prevalence and epidemiological associates of novel psychedelic use in the United States adult population. J. Psychopharmacol. 33, 1058–1067. doi: 10.1177/0269881119827796, PMID: PubMed DOI

Shapiro F. (2017). Eye movement desensitization and reprocessing (EMDR) therapy: basic principles, protocols, and procedures. New York: Guilford Publications.

Sloshower J., Guss J., Krause R., Wallace R. M., Williams M. T., Reed S., et al. . (2020). Psilocybin-assisted therapy of major depressive disorder using acceptance and commitment therapy as a therapeutic frame. J. Contextual Behav. Sci. 15, 12–19. doi: 10.1016/j.jcbs.2019.11.002 DOI

Swanson L. R. (2018). Unifying theories of psychedelic drug effects. Front. Pharmacol. 9:172. doi: 10.3389/fphar.2018.00172 PubMed DOI PMC

Szabo A., Kovacs A., Riba J., Djurovic S., Rajnavolgyi E., Frecska E. (2016). The endogenous hallucinogen and trace amine N, N-dimethyltryptamine (DMT) displays potent protective effects against hypoxia via sigma-1 receptor activation in human primary iPSC-derived cortical neurons and microglia-like immune cells. Front. Neurosci. 10:423. doi: 10.3389/fnins.2016.00423 PubMed DOI PMC

Tatarsky A. (2003). Harm reduction psychotherapy: extending the reach of traditional substance use treatment. J. Subst. Abus. Treat. 25, 249–256. doi: 10.1016/S0740-5472(03)00085-0, PMID: PubMed DOI

Trope A., Anderson B. T., Hooker A. R., Glick G., Stauffer C., Woolley J. D. (2019). Psychedelic-assisted group therapy: a systematic review. J. Psychoactive Drugs 51, 174–188. doi: 10.1080/02791072.2019.1593559, PMID: PubMed DOI PMC

Tylš F., Páleníček T., Horáček J. (2014). Psilocybin–summary of knowledge and new perspectives. Eur. Neuropsychopharmacol. 24, 342–356. doi: 10.1016/j.euroneuro.2013.12.006, PMID: PubMed DOI

Van Elk M., Yaden D. B. (2022). Pharmacological, neural, and psychological mechanisms underlying psychedelics: a critical review. Neurosci. Biobehav. Rev. 2022:104793. doi: 10.1016/j.neubiorev.2022.104793, PMID: PubMed DOI

Vedfelt O. (2002). The dimensions of dreams: The nature, function, and interpretation of dreams. London: Jessica Kingsley Publishers.

Watts R., Luoma J. B. (2020). The use of the psychological flexibility model to support psychedelic assisted therapy. J. Contextual Behav. Sci. 15, 92–102. doi: 10.1016/j.jcbs.2019.12.004 DOI

Westrum R., Dufrechou J. (2019). The psychedelics integration handbook. United States: Westrum and Derecho

Wolfson E. (2023). Psychedelic-supportive psychotherapy: a psychotherapeutic model for, before and beyond the medicine experience. J. Psychedelic Stud. 6, 191–202. doi: 10.1556/2054.2022.00192 DOI

Yaden D. B., Earp D., Graziosi M., Friedman-Wheeler D., Luoma J. B., Johnson M. W. (2022b). Psychedelics and psychotherapy: cognitive-behavioral approaches as default. Front. Psychol. 13:1604. doi: 10.3389/fpsyg.2022.873279 PubMed DOI PMC

Yaden D. B., Le Nguyen K. D., Kern M. L., Wintering N. A., Eichstaedt J. C., Schwartz H. A., et al. . (2017). The noetic quality: a multimethod exploratory study. Psychol. Conscious. Theory Res. Pract. 4, 54–62. doi: 10.1037/cns0000098 DOI

Yaden D. B., Potash J. B., Griffiths R. R. (2022a). Preparing for the bursting of the psychedelic hype bubble. JAMA Psychiatry 79, 943–944. doi: 10.1001/jamapsychiatry.2022.2546, PMID: PubMed DOI

Zinberg N. E. (1984). Drug, set and setting: the basis for controlled heroin use. New Haven, CT: Yale University Press.

The phenomenology of psilocybin's experience mediates subsequent persistent psychological effects independently of sex, previous experience, or setting